Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial Using Weekly Mitoxantrone Chemotherapy and G-CSF for the Treatment of Metastatic Hormone Refractory Prostate Cancer

NCT00003183 is registered in ClinicalTrials.gov with Hope Cancer Institute, Inc. as lead sponsor.

NCT NCT00003183
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003183 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial Using Weekly Mitoxantrone Chemotherapy and G-CSF for the Treatment of Metastatic Hormone Refractory Prostate Cancer
Lead sponsor
Hope Cancer Institute, Inc.
Phase
Phase 1/2
Overall status
Unknown status
Start date
March 31, 1997
Completion date
Not reported
Enrollment
64 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer